HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Ticlopidine

HCID 5472
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
55142-85-3
Standard SMILES
Clc1ccccc1CN1CCc2sccc2C1
InChIKey
PHWBOXQYWZNQIN-UHFFFAOYSA-N
Molecular formula
C14H14ClNS
Average molar mass
263.8 g/mol
Monoisotopic mass
263.0535483

Overview

Ticlopidine is a thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group. It has a role as a fibrin modulating drug, a hematologic agent, an anticoagulant, a platelet aggregation inhibitor and a P2Y12 receptor antagonist. It is a thienopyridine and a member of monochlorobenzenes.

Names & identifiers

Preferred name
Ticlopidine
IUPAC
5-[(2-chlorophenyl)methyl]-6,7-dihydro-4H-thieno[3,2-c]pyridine
English name
Ticlopidine
Molecular formula
C14H14ClNS
Molecular weight
263.79

Names & synonyms

ticlopidine55142-85-3TiclopidinaTiclopidinumTiclopidin-PurenDTXSID5023669OM90ZUW7M15-[(2-chlorophenyl)methyl]-4H,5H,6H,7H-thieno[3,2-c]pyridineCHEBI:9588DTXCID903669Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-
Show more names
TICIOPIDINEpcr5332TiclosinAnagregalCaudalinePCR 5332|||Ticlid5-(2-Chlorobenzyl)Ticlopidine USP/EP/BP
5-((2-chlorophenyl)methyl)-4H,5H,6H,7H-thieno(3,2-c)pyridineRefChem:57660B01AC05259-498-55-(2-Chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridineTiclopidinum [INN-Latin]Ticlopidina [INN-Spanish]PCR 5332

Database identifiers

CAS
55142-85-3
PubChem CID
5472
DTXSID

Properties

Computed structural propertiesFilling in

XLogP
3.6
Topological polar surface area
31.5 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
2
Heavy atoms
17
Formal charge
0
Complexity
261

Experimental & physicochemical properties

Drugs · 2 items

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP · 2 items

2.9

3.46

Solubility · 3 items

Freely soluble

2.19e-02 g/L

1 [ug/mL] (The mean of the results at pH 7.4)

Melting Pointapprox. 1 189°C
Physical DescriptionSolid
Collision Cross Section · 2 items

156.8 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID80202141]

153.84 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
210 · 210-212 °C
Boiling point
117 · 117-120 °C(Press: 0.5 Torr)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Other Safety InformationIMAP assessments - Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-: Environment tier I assessment

Toxicology

Hepatotoxicity · 1 item

Ticlopidine has been associated with serum enzyme elevations in approximately 4% of patients during therapy. These elevations are usually mild, asymptomatic and rarely require dose modification or stopping. Ticlopidine has also been associated with clinically apparent, acute liver injury. While these reactions are rare, more than 50 instances have been reported in the literature and some have been severe. The onset of symptoms is typically within 6 weeks (range 1 to 24 weeks) and marked by onset with fatigue, jaundice and itching. The usual pattern of liver enzyme elevations is cholestatic (~75%), but cases with mixed or hepatocellular enzyme elevations have also been described. Immunoallergic features such as fever, rash and eosinophilia can occur but are not common and, if present, are usually mild. Autoantibody formation is rare. Liver biopsy usually shows cholestatic hepatitis with mixed cellular infiltrates. Most cases are self-limited with recovery within 1 to 3 months, but isolated cases of prolonged jaundice or liver test abnormalities have been described, including at least one case of probable vanishing bile duct syndrome that eventually required liver transplantation. Ticlopidine therapy has also been associated with aplastic anemia and thrombotic thrombocytopenic purpura (TTP) that can be severe and lead to death; these patients may also have accompanying cholestatic liver injury.

Drug Induced Liver Injury · 6 items

Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)

ticlopidine

Ticlid

Antithrombotics

4

most-DILI-concern

EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Chemistry & industry

Pharmacology

ATC Code · 3 items

B01AC05

B - Blood and blood forming organs

QB - Blood and blood forming organs

Protein Binding · 1 item

Binds reversibly (98%) to plasma proteins, mainly to serum albumin and lipoproteins. The binding to albumin and lipoproteins is nonsaturable over a wide concentration range. Ticlopidine also binds to alpha-1 acid glycoprotein (about 15% or less).

Pharmacodynamics · 1 item

Ticlopidine is a prodrug that is metabolised to an as yet undetermined metabolite that acts as a platelet aggregation inhibitor. Inhibition of platelet aggregation causes a prolongation of bleeding time. In its prodrug form, ticlopidine has no significant in vitro activity at the concentrations attained in vivo.

Mechanism of Action · 1 item

The active metabolite of ticlopidine prevents binding of adenosine diphosphate (ADP) to its platelet receptor, impairing the ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. It is proposed that the inhibition involves a defect in the mobilization from the storage sites of the platelet granules to the outer membrane. No direct interference occurs with the GPIIb/IIIa receptor. As the glycoprotein GPIIb/IIIa complex is the major receptor for fibrinogen, its impaired activation prevents fibrinogen binding to platelets and inhibits platelet aggregation. By blocking the amplification of platelet activation by released ADP, platelet aggregation induced by agonists other than ADP is also inhibited by the active metabolite of ticlopidine.

Biological Half-Life · 1 item

Half-life following a single 250-mg dose is approximately 7.9 hours in subjects 20 to 43 years of age and 12.6 hours in subjects 65 to 76 years of age. With repeated dosing (250 mg twice a day), half-life is about 4 days in subjects 20 to 43 years of age and about 5 days in subjects 65 to 76 years of age.

Metabolism/Metabolites · 2 items

Ticlopidine is metabolized extensively by the liver with only trace amounts of intact drug detected. At least 20 metabolites have been identified.

Related reactions

21 records
New reaction record
HRID 270639 reaction equation
HRID 270639As reactant
HRID 270660 reaction equation
HRID 270660As product
HRID 358816 reaction equation
HRID 358816As product
HRID 358817 reaction equation
HRID 358817As reactant
HRID 568893 reaction equation
HRID 568893As product
HRID 568894 reaction equation
HRID 568894As product
HRID 804039 reaction equation
HRID 804039As reactant
HRID 838067 reaction equation
HRID 838067As product
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
DTXSID5023669
ChEMBL
CHEMBL833
ChEBI
CHEBI:9588
UNII
OM90ZUW7M1
EC Number
259-498-5
Nikkaji
J11.390E
Density
1.273 · 1.273±0.06 g/cm3(Predicted)
storage temp.
2 · 2-8°C(protect from light)
solubility
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
form
Solid
pka
7.1 · 7.10±0.20(Predicted)
color
Off-White to Pale Yellow
CAS DataBase Reference
55142 · 55142-85-3(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
90 ZUW7M1 · OM90ZUW7M1
ATC code
1 AC05 · B01AC05
NIST Chemistry Reference
3 · Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-(55142-85-3)
EPA Substance Registry System
3 · Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (55142-85-3)
Symbol(GHS)
7 · GHS07
Signal word
Warning
Hazard statements
315 · H315-H319
Precautionary statements
264 · P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Ticlopidine

11.7

49.3

The recommended dose of ticlopidine hydrochloride is 250 mg b.i.d. taken with food.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 500 mg/day, Lowest Therapeutic Dose (LTD): 6.3 mg/kg-day, and Screening Dose: 0.002 mg/kg-day.

6-Aug-16

Safety data

Signal word
Warning
Symbol(GHS)
GHS07
Hazard statements
H315-H319
Precautionary statements
P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

Ticlopidine has known human metabolites that include Thienodihydropyridinium and Ticlopidine S-oxide.

FDA Pharmacological Classification · 5 items

OM90ZUW7M1

TICLOPIDINE

Physiologic Effects [PE] - Decreased Platelet Aggregation

Established Pharmacologic Class [EPC] - Platelet Aggregation Inhibitor

Ticlopidine is a Platelet Aggregation Inhibitor. The physiologic effect of ticlopidine is by means of Decreased Platelet Aggregation.

MeSH Pharmacological Classification · 4 items

Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN.

Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.

Compounds that bind to and block the stimulation of PURINERGIC P2Y RECEPTORS. Included under this heading are antagonists for specific P2Y receptor subtypes.

Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 CYP2C19.

Absorption, Distribution and Excretion · 4 items

Absorption is greater than 80%. Food increases absorption by approximately 20%.

Ticlopidine is eliminated mostly in the urine (60%) and somewhat in the feces (23%).

The volume of distribution was not quantified.

Ticlopidine clearance was not quantified, but clearance decreases with age.

Cellular LocationsCytoplasm
Metabolite PathwaysTiclopidine Action Pathway

Uses & manufacturing

UsesUse (kg; approx.) in Germany (2009): >1000
Use ClassificationPharmaceuticals -> Blood and blood forming organs -> Anticoagulants
Applications · 3 items

UsesTiclopidine is an antiplatelet drug for the treatment of ischemic heart diseases.

UsesTiclopidine suppresses aggregation of thrombocytes and possesses antiaggregant activity. It is believed that its action is connected to its effect on thrombocyte membranes and the reduction in quantity of released adenosine diphosphate and serotonin, which facilitate aggregation of thrombocytes. In wide-ranging clinical trials, ticlopidine presented a number of advantages compared to aspirin.

General DescriptionTiclopidine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c]pyridine hydrochloride(Ticlid), is useful in reducing cardiac events in patients withunstable angina and cerebrovascular events in secondaryprevention of stroke. It belongs to the thienopyridine classand facilitated the development of clopidogrel. One of thedrawbacks to this agent is its side effect profile, whichincludes neutropenia, and patients receiving this antithromboticshould have their blood levels monitored. Its mechanismof action is similar to that of clopidogrel, in that itinhibits the purinergic receptors on platelets.

Upstream & downstream products

Upstream raw materials

Lithium tert-butoxideTiclopidine hydrochlorideNitroethylene2-ThiophenecarboxaldehydeNitromethaneTosyl chlorideDiethyl etherPotassium borohydrideSodium hydroxideethylthiolpheneDiisopropyl ethern-ButyllithiumSodium borohydrideThieno[3,2-d]pyrimidine-7-methanamine (9CI)1H-Pyrrolo[3,2-c]pyridine, 6-methyl-2-(2-Chlorophenyl)acetonitrile

Additional notes

DefinitionChEBI: A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.